Lori Kay
Psychiatric/Mental Health · Lake Charles, LANPI 1447703251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,708, 3.3 times the $812 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$832
- Otsuka America Pharmaceutical, Inc.$823
- Alkermes, Inc.$625
- plus $3K from 11 others
What the payments were for
- Food & beverage$8,74597%
- Education$2763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,570 |
| Teva Pharmaceuticals USA, Inc. | 50 | $1,546 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,013 |
| Neurocrine Biosciences, Inc. | 36 | $832 |
| Otsuka America Pharmaceutical, Inc. | 16 | $823 |
| Alkermes, Inc. | 19 | $625 |
| Axsome Therapeutics, Inc. | 22 | $620 |
| E.r. Squibb & Sons, L.L.C. | 17 | $478 |
| Vanda Pharmaceuticals Inc. | 14 | $395 |
| Johnson & Johnson | 14 | $330 |
| Indivior Inc. | 15 | $274 |
| Gilead | 2 | $115 |
| AstraZeneca | 1 | $114 |
| Boehringer Ingelheim | 1 | $114 |
| Sunovion Pharmaceuticals Inc. | 6 | $102 |
| Noven Therapeutics, LLC | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,807
- UZEDY$581
- VRAYLAR$472
- Auvelity$466
- ABILIFY MAINTENA$446
- CAPLYTA$349
- ABILIFY ASIMTUFII$336
- Fanapt$243
- COBENFY$238
- Austedo XR$231
- REXULTI$221
- UBRELVY$220
- FARXIGA$114
- JARDIANCE$114
How this compares
$9,021 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 83 | $222,816 |
| IngrezzaValbenazine Tosylate | 26 | $216,243 |
| CaplytaLumateperone Tosylate | 82 | $140,963 |
| RexultiBrexpiprazole | 53 | $80,070 |
| VraylarCariprazine Hcl | 41 | $60,687 |
| AustedoDeutetrabenazine | 12 | $45,527 |
| AristadaAripiprazole Lauroxil | 12 | $45,527 |
| PerserisRisperidone | 12 | $35,345 |
| Abilify MaintenaAripiprazole | 13 | $27,791 |
| Aripiprazole | 93 | $25,289 |
| Divalproex Sodium ErDivalproex Sodium | 111 | $5,736 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,595 |
| Paliperidone ErPaliperidone | 31 | $5,335 |
| Chlorpromazine Hcl | 21 | $5,144 |
| BelsomraSuvorexant | 11 | $4,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $330 | $222,81683 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $832 | $216,24326 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,013 | $140,96382 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $823 | $107,86166 claims |
| AbbVieVraylar | $1,570 | $60,68741 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,546 | $45,52712 claims |
| Alkermes, Inc.Aristada | $625 | $45,52712 claims |
| Indivior Inc.Perseris | $274 | $35,34512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lake Charles
- Sattaria DilksLake Charles$57K
- Michelle DyerLake Charles$33K
- Erica HessiferLake Charles$13K
- Candyce BrownLake Charles$13K
- Bethanne CarsonLake Charles$12K
- Morgan UnserLake Charles$9K
- Eric RachalLake Charles$9K
- Valarie ClarkLake Charles$8K
- Julie DyrekLake Charles$8K
- Halie OryLake Charles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.